These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 6188898)

  • 61. Hemodynamic comparison of combined therapy by nitroglycerin tape and ibopamine with combination of nitroglycerin tape and nifedipine.
    Taniguchi K; Tsujibayashi T; Itoh H
    Cardiology; 1990; 77 Suppl 5():49-56. PubMed ID: 1703920
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Effects of ibopamine on the increase in plasma norepinephrine levels during exercise in congestive heart failure.
    van Veldhuisen DJ; Girbes AR; van den Broek SA; de Graeff PA; van Gilst WH; Lie KI
    Am J Cardiol; 1993 Apr; 71(11):992-4. PubMed ID: 8465795
    [No Abstract]   [Full Text] [Related]  

  • 63. [Echocardiographic and polygraphic study of acute/effects of Ibopamine on cardiac performance].
    Ladelli L; Pezzano A; Sala G; Mangiavacchi M; Cadel A; Brusoni B
    G Ital Cardiol; 1983 Oct; 13(10):239-48. PubMed ID: 6667808
    [TBL] [Abstract][Full Text] [Related]  

  • 64. [Strain gauge plethysmography in the evaluation of the effect of acute administration of ibopamine on the peripheral circulation of normal subjects].
    Longhini C; Ansani L; Musacci GF; Fratti D; Toselli T; Lupato L
    Cardiologia; 1982 Dec; 27(12):1189-95. PubMed ID: 6927477
    [No Abstract]   [Full Text] [Related]  

  • 65. [Ibopamine--clinical results].
    Kleber FX
    Z Kardiol; 1991; 80 Suppl 8():71-6. PubMed ID: 1686695
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Noninvasive assessment of diastolic and systolic properties of ibopamine in patients with congestive heart failure.
    Stoddard MF; Chaitman BR; Byers SL; Mrosek D; Labovitz AJ
    Am Heart J; 1989 Feb; 117(2):395-402. PubMed ID: 2916412
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Absence of proarrhythmic effects of ibopamine in patients with congestive heart failure.
    Caponnetto S; Terrachini V; Canale C; Bruzzone F; Licciardello L; Marchetti GV
    J Cardiovasc Pharmacol; 1989; 14 Suppl 8():S104-10. PubMed ID: 2483435
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Inhibition of prolactin and aldosterone secretion by the dopamine derivative ibopamine.
    Rolandi E; Marchetti G; Franceschini R; Cicchetti V; Gianrossi R; Cantoni V; Barreca T
    Eur J Clin Pharmacol; 1986; 29(5):629-30. PubMed ID: 3956568
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Evaluation of ibopamine plus prazosin in congestive heart failure.
    Naidoo DP; Rocke A; Mitha AS
    S Afr Med J; 1998 Feb; 88 Suppl 1():C25-31. PubMed ID: 9542492
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Double-blind haemodynamic study of a new dopamine derivative (diisobutyric ester of N-methyl-dopamine) orally active in chronic congestive heart failure.
    Mengeot P; Piette F; Mirgaux M
    G Ital Cardiol; 1981; 11(11):1738-42. PubMed ID: 7343377
    [No Abstract]   [Full Text] [Related]  

  • 71. Comparative effects of ibopamine and captopril in mild congestive heart failure. Focus on the long-term effects of inodilation on ventricular arrhythmias.
    Cocchieri M; Alunni GF; Del Favero A; Fortunati F; Bardelli G; Capponi EA; Regi L; Boschetti E
    Cardiology; 1990; 77 Suppl 5():36-42. PubMed ID: 2126222
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Humoral and renal effects of ibopamine in normal subjects.
    Incerti PL; Badalamenti S; Lorenzano E; Graziani G; Morganti A; Salerno F; Ghirardi P
    Arzneimittelforschung; 1986 Feb; 36(2A):405-7. PubMed ID: 3518727
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Ibopamine vs. digoxin in chronic heart failure: a double-blind, crossover study.
    Alicandri C; Fariello R; Boni E; Zaninelli A; Muiesan G
    J Cardiovasc Pharmacol; 1989; 14 Suppl 8():S77-82. PubMed ID: 2483444
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Safety of ibopamine therapy in congestive heart failure. Ibopamine cohort study: baseline and 1-year results.
    Sher D; Licciardello L; Ferrari V; Sirtori F; Cesana B
    Arzneimittelforschung; 1991 Apr; 41(4):402-9. PubMed ID: 1859514
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Ibopamine as a valuable adjunct and substitute for dopamine in bridging therapy before heart transplantation.
    Kleber FX; Sabin GV; Thyroff-Friesinger U; Cabell B; Glogar D
    Cardiology; 1992; 81(2-3):121-4. PubMed ID: 1286470
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Ibopamine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in congestive heart failure.
    Spencer C; Faulds D; Fitton A
    Drugs Aging; 1993; 3(6):556-84. PubMed ID: 7906158
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Ibopamine as a substitute for digitalis in patients with congestive heart failure on chronic digoxin therapy. Smith Kline and French Ibopamine Group.
    Cavalli A; Riva E; Schleman M; Abbondati G; Fuccella LM
    Int J Cardiol; 1989 Mar; 22(3):381-7. PubMed ID: 2707917
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Analysis of the positive inotropic effect of ibopamine in the blood-perfused canine papillary muscle.
    Kawahara K; Inui J
    J Cardiovasc Pharmacol; 1985; 7(2):316-20. PubMed ID: 2581086
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Effects of ibopamine on exercise-induced increase in norepinephrine in normal men.
    Girbes AR; Van Veldhuisen DJ; Grevink RG; Smith AJ; Reitsma WD
    J Cardiovasc Pharmacol; 1992 Mar; 19(3):371-4. PubMed ID: 1378116
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Acute hemodynamic effect of oral MDL 17,043 in severe congestive heart failure.
    Uretsky BF; Generalovich T; Reddy PS; Salerni R; Valdes AM; Spangenberg RB; Lang JF; Okerholm RA
    Am J Cardiol; 1984 Aug; 54(3):357-62. PubMed ID: 6235735
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.